Bookmark and Share
Succinic Acid (CID 1110) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(7)
 
 
Inactive(387)
 
 
Inconclusive(18)
 
 
Unspecified(21)
 
 
Top Targets:
NR LBD PPAR(24)
 
 
 
NR LBD AR(21)
 
 
 
NR LBD ER(21)
 
 
 
NR LBD VDR(13)
 
 
 
NR LBD Fxr(12)
 
 
 
BioAssay Types:
Confirmatory(248)
 
 
 
Literature(90)
 
 
 
 
 
Summary(72)
 
 
 
Screening(7)
 
 
BioActivity Types:
Potency(299)
 
 
 
IC50(8)
 
 
 
Kd(5)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 192    Data Row: 433   Total Pages: 22   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103179217]
IC50 0.0013Anti-Herpes simplex virus type-1 activity in vero cells using plaque inhibition assay [AID216185, Type: Literature]
View
2
[SID103179217]
IC50 3Inhibition of 2-oxoglutarate-dependent human recombinant HIF PHD2 preincubated for 1 hr [AID344926, Type: Literature]Egl nine homolog 1 [gi:32129514]
View
3
[SID46391683]
Kd 2400Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB [AID977611, Type: Literature]Chain A, Aspartate Aminotransferase Mutant Atb17139S142N WITH SUCCINIC ACID [gi:7245555]
View
4
[SID46391683]
Kd 2400Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB [AID977611, Type: Literature]Chain A, Aspartate Aminotransferase Mutant Atb17139S142N WITH SUCCINIC ACID [gi:7245555]
View
5
[SID46391683]
Experimentally measured binding affinity data derived from PDB [AID1811, Type: Literature]Chain A, Aspartate Aminotransferase Mutant Atb17139S142N WITH SUCCINIC ACID [gi:7245555]
View
6
[SID48416561]
DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
7
[SID406687]
NCI In Vivo Anticancer Drug Screen. Data for tumor model B16 Melanoma (subcutaneous) in B6D2F1 (BDF1) mice [AID194, Type: other]
View
8
[SID103179217]
IC50 85.3Inhibition of human PHD2 at 293K temperature by solvent relaxation technique [AID446353, Type: Literature]Egl nine homolog 1 [gi:32129514]
View
9
[SID103179217]
IC50 85.3Destabilizing effect on human recombinant PHD2 (181-426) expressed in Escherichia coli BL21 (DE3) assessed as half life by limited trypsinolysis/MALDI-MS analysis in presence of ferrous ion [AID349748, Type: Literature]
View
10
[SID103179217]
Kd 100Binding affinity to human PHD2-Mn(II) using 12.5% H2O/87.5% D2O MQC spectrometer operated at 500 MHz at 298K temperature [AID446356, Type: Literature]Egl nine homolog 1 [gi:32129514]
View
11
[SID103179217]
Kd 100Binding affinity to human PHD2 by nondenaturing ESI-MS [AID446352, Type: Literature]Egl nine homolog 1 [gi:32129514]
View
12
[SID103179217]
IC50 320Inhibition of 2-oxoglutarate-dependent human JMJD2E preincubated for 30 mins by FDH coupled assay [AID344918, Type: Literature]
View
13
[SID103179217]
IC50 710Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of excess H3K9me3 peptide and 10 uM Fe2 by FDH coupled assay [AID344917, Type: Literature]
View
14
[SID103179217]
Kd 1450Binding affinity to Pyrococcus horikoshii sodium-coupled aspartate transporter [AID328866, Type: Literature]
View
15
[SID103179217]
IC50 10000Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of excess 2-oxoglutarate and 10 uM Fe2 by FDH coupled assay [AID344916, Type: Literature]
View
16
[SID103179217]
IC50 10000Inhibition of PHD2 (unknown origin) [AID721521, Type: Literature]Egl nine homolog 1 [gi:32129514]
View
17
[SID103179217]
Inhibition of human recombinant PHD2 (181-426) expressed in Escherichia coli BL21 (DE3) by TR-FRET assay [AID349747, Type: Literature]
View
18
[SID103179217]
Aqueous solubility [AID19262, Type: Literature]
View
19
[SID103179217]
Protein interaction energy by using binding affinity towards human L-xylulose reductase enzyme [AID95754, Type: Literature]
View
20
[SID103179217]
Antileukemic activity of compound against the P-388 lymphocytic leukemic BDF1 male mice at 0.6(mg/kg)/day, administered intraperitoneally; 10.7/9.66 (Treated/control) [AID110255, Type: Literature]
View